Contineum Therapeutics, Inc. Board of Directors

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Mr. Carmine N. Stengone MBA, MS

Mr. Carmine N. Stengone MBA, MS

President, CEO, Secretary & Director

Mr. Michael Mayberry

Mr. Michael Mayberry

Senior Director & Corporate Controller

Mr. John Healy

Mr. John Healy

General Counsel & Corporate Secretary

Mr. Steve E. Kunszabo

Mr. Steve E. Kunszabo

Senior Director of Investor Relations & Corporate Communications

Mr. Austin Chen Ph.D.

Mr. Austin Chen Ph.D.

Senior VP & Head of Research

Morgan Paulsen

Morgan Paulsen

Senior Manager of Accounting

Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D.

Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D.

Chief Medical Officer & Senior VP of Clinical Development

Mr. Peter T. Slover CPA

Mr. Peter T. Slover CPA

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.